GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Capex-to-Operating-Income

ZBIO (Zenas BioPharma) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Zenas BioPharma's Capital Expenditure for the three months ended in Dec. 2024 was $-0.07 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-55.62 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Zenas BioPharma Capex-to-Operating-Income Historical Data

The historical data trend for Zenas BioPharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Capex-to-Operating-Income Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24
Capex-to-Operating-Income
- - -

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Zenas BioPharma's Capex-to-Operating-Income

For the Biotechnology subindustry, Zenas BioPharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenas BioPharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Capex-to-Operating-Income falls into.


;
;

Zenas BioPharma Capex-to-Operating-Income Calculation

Zenas BioPharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.131) / -163.888
=N/A

Zenas BioPharma's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.074) / -55.623
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zenas BioPharma  (NAS:ZBIO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Zenas BioPharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.